Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019158 (hepatitis)
 30,205 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The prognostic significance of the HBe-antigen (HBeAg) in the course and outcome of type B hepatitis was studied prospectively in 71 susceptible oncology patients. The patients had been exposed to tumor cell vaccines inadvertently contaminated with hepatitis B surface antigen (HBsAg)-containing plasma. Forty-five patients (63%) were infected. These 45 showed three types of acute seroresponse: HBsAg and HBeAg, 28 patients (62%); HBsAg alone, 8 patients (18%); and a primary antibody to HBsAg (anti-HBs) response, 9 patients (20%). There was no significant difference in acute course and outcome between the two HBs-antigenemic groups. All primary anti-HBs responders had asymptomatic infections. Seventeen patients receiving chemotherapy during the period of hepatitis B exposure were significantly more prone to symptomatic infection with acute HBs-antigenemia, and 2 of these patients developed chronic active hepatitis. The HBeAg is common early in acute hepatitis B among solid tumor patients and at this stage in disease has no prognostic significance independent of HBsAg.
 ...
PMID:HBe-Antigen in the course and prognosis of hepatitis B infection: a prospective study. 735 48

Fibrosing cholestatic hepatitis (FCH) is a variant of viral hepatitis reported in hepatitis B virus or hepatitis C virus infected liver, renal or bone transplantation recipients and in leukemia and lymphoma patients after conventional cytotoxic chemotherapy. FCH constitutes a well-described form of fulminant hepatitis having extensive fibrosis and severe cholestasis as its most characteristic pathological findings. Here, we report a case of a 49-year-old patient diagnosed with small-cell lung cancer who developed this condition following conventional chemotherapy-induced immunosuppression. This is the first reported case in the literature of FCH after conventional chemotherapy for a solid tumor. In addition to a detailed report of the case, a physiopathological examination of this potentially life-threatening condition and its treatment options are discussed.
 ...
PMID:Fibrosing cholestatic hepatitis following cytotoxic chemotherapy for small-cell lung cancer. 1943 74

Hepatitis B virus (HBV) reactivation during immunosuppressive therapy is common in patients with solid tumor or hematological malignancies. It is associated with significant morbidity and mortality due to hepatitis flare and/or hepatic decompensation. These consequences arising from HBV reactivation are, however, largely preventable. Routine screening for HBV serologic status is recommended for all cancer patients undergoing chemotherapy or biologics. By recognizing different serological patterns (which represent either overt or occult HBV infection) and the types of immunosuppressive therapies prescribed, a risk-adapted approach can be established. Prophylactic therapy with nucleos(t)ide analogues (prior to or concomitantly with the commencement of immunosuppressive therapies) is more effective than pre-emptive therapy (starting antiviral when HBV DNA level is rising) in high-risk individuals. Entecavir has been proven to be more effective than lamivudine according to recent studies. Close monitoring of serum HBV level is the preferred strategy in low-risk patients. However, the optimal interval of DNA monitoring and the duration of therapy remain unknown.
...
PMID:Prevention and management of hepatitis B virus reactivation in cancer patients. 2673 35